Physician profile
Yvette Cebrian
NPI 1538587449
$1,227.72
in general payments reported to CMS, 2019-2025
17 companies · $126 in 2025
The $126 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $115 · 2021: $89.34 · 2022: $159 · 2023: $308 · 2024: $241 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $222.41 | 2019-2025 | |
| Corium, LLC | $191.30 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $131.73 | 2019-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $110.37 | 2022-2024 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $99.70 | 2020-2025 | Bexsero, Menveo |
| Sanofi Pasteur INC. | $86.07 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $67.62 | 2020-2022 | |
| Cranial Technologies, INC | $64.81 | 2022-2024 | Doc Band |
| Seqirus USA INC | $43.71 | 2022-2025 | Flucelvax |
| Verrica Pharmaceuticals INC. | $33.35 | 2023 | Ycanth |
| Ultragenyx Pharmaceutical INC. | $32.33 | 2020-2022 | |
| Adlon Therapeutics L.P. | $29.17 | 2020-2021 | |
| Cumberland Pharmaceuticals, INC. | $27.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.01 | 2022 | |
| Phadia US INC. | $22.24 | 2025 | Immunocap |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $21.09 | 2021 | |
| Kyowa Kirin, INC. | $17.11 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette Cebrian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.